ATE100804T1 - Substituierte chromane fuer die behandlung von asthma, arthritis und aehnlichen krankheiten. - Google Patents

Substituierte chromane fuer die behandlung von asthma, arthritis und aehnlichen krankheiten.

Info

Publication number
ATE100804T1
ATE100804T1 AT90303443T AT90303443T ATE100804T1 AT E100804 T1 ATE100804 T1 AT E100804T1 AT 90303443 T AT90303443 T AT 90303443T AT 90303443 T AT90303443 T AT 90303443T AT E100804 T1 ATE100804 T1 AT E100804T1
Authority
AT
Austria
Prior art keywords
treatment
asthma
arthritis
substituted
chromanas
Prior art date
Application number
AT90303443T
Other languages
English (en)
Inventor
James Frederick Eggler
Hiroko Masamune
Anthony Marfat
Lawrence Sherman Melvin Jr
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE100804T1 publication Critical patent/ATE100804T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
AT90303443T 1989-04-07 1990-03-30 Substituierte chromane fuer die behandlung von asthma, arthritis und aehnlichen krankheiten. ATE100804T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1989/001457 WO1990012010A1 (en) 1989-04-07 1989-04-07 Substituted chromans in the treatment of asthma, arthritis and related diseases

Publications (1)

Publication Number Publication Date
ATE100804T1 true ATE100804T1 (de) 1994-02-15

Family

ID=22214926

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90303443T ATE100804T1 (de) 1989-04-07 1990-03-30 Substituierte chromane fuer die behandlung von asthma, arthritis und aehnlichen krankheiten.

Country Status (12)

Country Link
US (1) US5298512A (de)
EP (1) EP0391625B1 (de)
JP (1) JPH0753726B2 (de)
AT (1) ATE100804T1 (de)
CA (1) CA2013894A1 (de)
DE (1) DE69006243T2 (de)
DK (1) DK0391625T3 (de)
ES (1) ES2062345T3 (de)
FI (1) FI914683A0 (de)
IE (1) IE901241L (de)
PT (1) PT93674A (de)
WO (1) WO1990012010A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676056B1 (fr) * 1991-05-03 1993-07-16 Adir Nouveaux derives du benzopyranne leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5149703A (en) * 1991-09-06 1992-09-22 Merck Frosst Canada, Inc. Quinoline-substituted chromans and related compounds as leukotriene antagonists
MX9300312A (es) * 1992-01-23 1993-07-31 Pfizer Antagonistas benzopiranicos y relacionado de ltb.
US5451603A (en) * 1993-03-11 1995-09-19 Zymogenetics, Inc. 3,4-diarylchromans for treatment of dermatitis
US5698550A (en) * 1993-06-14 1997-12-16 Pfizer Inc. Tetralin and chroman derivatives useful in the treatment of asthma, arthritis and related diseases
US5482942A (en) * 1994-06-28 1996-01-09 American Home Products Corporation (3,4-dioxocyclobuten-1-yl)chromene, indene, and dihydronaphthalenone derivatives as smooth muscle relaxants
US5952326A (en) * 1997-12-10 1999-09-14 Pfizer Inc. Tetralin and chroman derivatives useful in the treatment of asthma, arthritis and related diseases
WO2000078766A1 (en) * 1999-06-22 2000-12-28 Mount Sinai Hospital Difuropyrone derivatives
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US7851486B2 (en) * 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
US7507531B2 (en) * 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
AU2003301305A1 (en) * 2002-10-17 2004-05-04 Decode Genetics Ehf. Susceptibility gene for myocardial infarction; methods of treatment
CA2539276A1 (en) * 2003-09-17 2005-03-31 Decode Genetics Ehf. Methods of preventing or treating recurrence of myocardial infarction
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
EP3791880A1 (de) 2009-04-29 2021-03-17 Amarin Pharmaceuticals Ireland Limited Pharmazeutische zusammensetzungen enthaltend epa
WO2016122500A1 (en) 2015-01-28 2016-08-04 Smith & Nephew, Inc. Tissue resection system
WO2016205197A1 (en) 2015-06-18 2016-12-22 Covidien Lp Surgical instrument with suction control
KR102524421B1 (ko) * 2017-09-07 2023-04-21 뉴소아라 바이오파마 컴퍼니 리미티드 벤젠 축합 헤테로환 유도체 및 이를 포함하는 약학 조성물
US11883058B2 (en) 2019-03-26 2024-01-30 Covidien Lp Jaw members, end effector assemblies, and ultrasonic surgical instruments including the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3553093A (en) * 1965-03-19 1971-01-05 Xerox Corp Color photoelectrophoretic imaging process
US3936461A (en) * 1973-09-24 1976-02-03 Warner-Lambert Company Substituted 4-benzylquinolines
US4127669A (en) * 1977-10-13 1978-11-28 Warner-Lambert Company [(4-Oxo-4H-1-benzopyran-3-yl)oxy] acetic acids and derivatives
US4563468A (en) * 1979-09-13 1986-01-07 Burroughs Wellcome Co. Chemotherapeutic agents
EP0126311B1 (de) * 1983-05-18 1989-09-13 Beecham Group Plc Benzopyran-Derivate.
US4661596A (en) * 1985-02-21 1987-04-28 American Home Products Corporation Quinolinyl (or pyridinyl) methoxy substituted naphthalene compounds as antiallergic agents
US4642347A (en) * 1985-05-21 1987-02-10 American Home Products Corporation 3(2-quinolinylalkoxy)phenols
US4889941A (en) * 1987-04-23 1989-12-26 Fisons Corporation Synthetic flavonoids as inhibitors of leukotrienes and 5-lipoxygenase
US4889871A (en) * 1987-05-29 1989-12-26 G. D. Searle & Co. Alkoxy-substituted dihydrobenzopyran-2-carboxylate derivatives
MX13485A (es) * 1987-10-19 1993-05-01 Pfizer Procedimiento para obtener tetralinas, cromados y compuestos relacionados, sustituidos

Also Published As

Publication number Publication date
IE901241L (en) 1990-10-07
DE69006243D1 (de) 1994-03-10
ES2062345T3 (es) 1994-12-16
WO1990012010A1 (en) 1990-10-18
EP0391625B1 (de) 1994-01-26
CA2013894A1 (en) 1990-10-07
DE69006243T2 (de) 1994-05-05
JPH0753726B2 (ja) 1995-06-07
PT93674A (pt) 1990-11-20
FI914683A0 (fi) 1991-10-04
EP0391625A1 (de) 1990-10-10
DK0391625T3 (da) 1994-02-28
JPH02290869A (ja) 1990-11-30
US5298512A (en) 1994-03-29

Similar Documents

Publication Publication Date Title
ATE100804T1 (de) Substituierte chromane fuer die behandlung von asthma, arthritis und aehnlichen krankheiten.
MY104341A (en) Substituted tetralins,chromans and related compounds in the treatment of asthma,arthritis and related diseases
BRPI9917862B8 (pt) dihidropirimidinas, bem como processo para a preparação e aplicação das mesmas.
ATE175194T1 (de) (e)-20(22)-dehydrovitamin-d-verbindungen
ES2083396T3 (es) Acidos fenilalcan(en)oicos.
ATE99307T1 (de) Substituierte chromane und verwandte verbindungen fuer die behandlung von asthma.
ES2109229T3 (es) Sulfonamidas sustituidas y compuestos relacionados para el tratamiento del asma, la artritis y enfermedades relacionadas.
DE69007837T2 (de) Substituierte 1-[3-Heteroarylmethoxyphenyl]alkanole und verwandte Verbindungen, für die Behandlung von Asthma, Arthritis und ähnlichen Krankheiten.
DK0891326T3 (da) Nye D-vitaminanaloger
FR2652079B1 (fr) Procede de preparation d'argiles pontees et argiles pontees obtenues selon ce procede.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee